Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHVF)
OTHER OTC:RHHVF
Holding RHHVF?
Track your performance easily
RHHVF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$233.12 - $337.19
Previous Close$334.35
Volume510.00
Average Volume (3M)9.92K
Market Cap
$272.09B
Enterprise Value$297.51B
Total Cash (Recent Filing)CHF7.51B
Total Debt (Recent Filing)CHF25.39B
Price to Earnings (P/E)22.3
Beta0.33
Next Earnings
Jan 30, 2025EPS Estimate
$9.78Last Dividend Ex-Date
Mar 14, 2024Dividend Yield3.26%
Share Statistics
EPS (TTM)15.00
Shares Outstanding800,578,845
10 Day Avg. Volume15,610
30 Day Avg. Volume9,918
Standard Deviation0.05
R-Squared0.21
Alpha-0.00086
Financial Highlights & Ratios
Price to Book (P/B)93.14
Price to Sales (P/S)3.40
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$321.30Price Target Upside-4.25% Downside
Rating ConsensusHold
Number of Analyst Covering12
Roche Holding AG News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPositive top-line phase 1 data for oral once-daily GLP-1R agonist CT-996 in people with obesity without diabetes shows 6.1% placebo-adjusted weight loss.
Earnings PotentialBetter than anticipated cost control results in a 5% upgrade to 2024 Core EPS and leads to a 7-10% upgrade to 2025-30 Core EPS.
Sales GrowthThree FDA approved drugs (Phesgo, Vabysmo, Hemlibra) and Diagnostics are expected to drive faster sales growth and greater operating leverage.
Bears Say
Analyst RatingMaintain Underweight rating ahead of the CT-388/CT-996 data to be presented at the EASD meeting.
Data TransparencyImportant baseline characteristics and PK/PD parameters are not disclosed, making cross-trial comparisons difficult.
Growth RisksThe largest downside risks include Vabysmo and Phesgo delivering only the consensus forecasts and the group margin not expanding between 2023 and 2029.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
11.50% Mutual Funds
9.41% Other Institutional Investors
79.09% Public Companies and
Individual Investors
RHHVF FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $233.12 and its highest was $337.19 in the past 12 months.
What is Roche Holding AG’s market cap?
Currently, no data Available
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 30, 2025 which is in 152 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 25, 2024. The company reported $11.981 earnings per share for the quarter, beating the consensus estimate of $10.968 by $1.013.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $11.32 which represents an annual dividend yield of 3.26%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is $9.78.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $11.981 in its last earnings report, beating expectations of $10.968. Following the earnings report the stock price went up 1.679%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHVF
---
Roche Holding AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$321.30 (-4.25% Downside)
$321.30 (-4.25% Downside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.09%
12-Months-Change
Fundamentals
Return on Equity
38.68%
Trailing 12-Months
Asset Growth
13.03%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
---
RHHVF Company Deck
---
RHHVF Earnings Call
Q2 2024
0:00 / 0:00
---
RHHVF Stock 12 Month Forecast
Average Price Target
$321.30
▼(-4.25% Downside)
Technical Analysis
Best Analysts Covering RHHVF
1 Year
1 Year Success Rate
25/40 ratings generated profit
1 Year Average Return
+3.21%
reiterated a sell rating last month
Copying Richard Vosser's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +3.21% per trade.
---